Drug Education Guide

Avelumab (Nurse)

Immunotherapy Monoclonal antibody PD-L1 inhibitor

Avelumab (Nurse)

Immunotherapy Monoclonal antibody PD-L1 inhibitor
Light Sensitive Fall Risk
Medication Basics

Drug Name

Avelumab (Brand names: Bavencio®)

Purpose / Indication

Used to treat certain cancers, including Merkel cell carcinoma, urothelial carcinoma, and some cases of renal cell carcinoma when ordered by the oncology team. Verify indication, regimen, line of therapy, biomarker requirements, and institutional protocol before administration.

Dosage & Administration

Dose Schedule

Often administered as an intravenous infusion every 2 weeks, but the exact dose and schedule depend on diagnosis, body weight, combination therapy, and institutional protocol.

Route

IV (Intravenous)

Timing Considerations

Confirm treatment plan, cycle timing, combination agents, hold parameters, infusion duration, and any required pre-infusion assessments before administration.

Time of Day

Flexible

Special Instructions

Assess baseline symptoms, review labs, confirm consent, educate on immune-related or targeted-therapy toxicities, and follow institutional hypersensitivity/infusion reaction procedures.

Injection Techniques

Administer by IV infusion per institutional policy and current prescribing information. Do not administer IV push or bolus unless specifically supported by policy.

Mechanism of Action

Mechanism

Avelumab is a PD-L1 blocking monoclonal antibody that inhibits PD-L1 interaction with PD-1 and B7.1 receptors, supporting T-cell mediated antitumor immune activity.

13 More Sections — Members Only

Free membership unlocks the complete guide.

  • Side Effects
  • Drug Interactions
  • Contraindications
  • Monitoring
  • Adherence
  • + 8 more…
Was this guide helpful?